Zentalis Pharmaceuticals Llc (ZNTL) - Total Liabilities
Based on the latest financial reports, Zentalis Pharmaceuticals Llc (ZNTL) has total liabilities worth $72.76 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zentalis Pharmaceuticals Llc - Total Liabilities Trend (2018–2025)
This chart illustrates how Zentalis Pharmaceuticals Llc's total liabilities have evolved over time, based on quarterly financial data. See Zentalis Pharmaceuticals Llc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Zentalis Pharmaceuticals Llc Competitors by Total Liabilities
The table below lists competitors of Zentalis Pharmaceuticals Llc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Soren Acquisition Corp. Class A Ordinary Shares
NASDAQ:SORN
|
USA | $297.17K |
|
ProCap Acquisition Corp Class A Ordinary Shares
NASDAQ:PCAP
|
USA | $11.39 Million |
|
LIFELINE SPAC I OYJ A EO1
F:0CD
|
Germany | €9.90 Million |
|
Federal Corp
TW:2102
|
Taiwan | NT$6.89 Billion |
|
Transportadora de Gas del Norte SA Class C
BA:TGNO4
|
Argentina | AR$281.59 Billion |
|
Doosan Co Ltd
KO:000157
|
Korea | ₩20.11 Trillion |
|
Bourse Direct SA
PA:BSD
|
France | €1.28 Billion |
|
Tangshan Jidong Equipment Engineering Co Ltd
SHE:000856
|
China | CN¥1.81 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Zentalis Pharmaceuticals Llc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ZNTL company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zentalis Pharmaceuticals Llc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zentalis Pharmaceuticals Llc (2018–2025)
The table below shows the annual total liabilities of Zentalis Pharmaceuticals Llc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $72.76 Million | -21.89% |
| 2024-12-31 | $93.15 Million | -25.26% |
| 2023-12-31 | $124.64 Million | +4.36% |
| 2022-12-31 | $119.43 Million | +11.06% |
| 2021-12-31 | $107.54 Million | +234.21% |
| 2020-12-31 | $32.18 Million | +62.42% |
| 2019-12-31 | $19.81 Million | +127.92% |
| 2018-12-31 | $8.69 Million | -- |
About Zentalis Pharmaceuticals Llc
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosert… Read more